Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, statistical analysis was conducted using SPSS 19.0 software and the expression levels of miR-21 and Bcl-2 within DLBCL tissues were significantly upregulated when compared to those in normal tissues (P<0.01).
|
29067124 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared to the HCV-negative controls, patients with HCV-positive de novo DLBCL had differential expression of genes that regulate innate immune response and modulate apoptotic pathways, have higher proliferative index, and lack BCL2 translocations.
|
28949959 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The impact of MYC proto-oncogene, basic helix-loop-helix (MYC) translocations (with or without additional rearrangements involving the B-cell lymphoma 2 [BCL2] or BCL6 genes) on the response to salvage therapy and survival in patients with diffuse large B-cell lymphoma (DLBCL) who experience primary treatment failure is not well defined.
|
28749548 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cases of DLBCL of the non-GC type with BCL2 gene aberration are accompanied by a significantly worse prognosis as opposed to cases without such gene abnormalities.
|
19783718 |
2009 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nodal DLBCLs showed an increased tendency for 18q amplification and BCL2 protein overexpression compared with extranodal and mixed tumors.
|
21832150 |
2011 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrated that concurrent inhibition of BCL2 and MCL1 with ABT-199 and HHT induced significant synthetic lethality in most BCL2-expressing DLBCL cell lines.
|
26467384 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To determine whether cellular factors can be combined with the IPI to more accurately predict outcome, we have analyzed 177 presentation nodal DLBCLs for the expression of bcl-2 and a germinal center (GC) phenotype (defined by expression of bcl-6 and CD10).
|
11830458 |
2002 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The BCL2/Ki-67 index demonstrated a significant association with decreased overall and progression free survival of patients with DLBCL, particularly for the germinal center B-cell-like subtype of DLBCL.
|
28927145 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/THs) include a group of diffuse large B-cell lymphomas (DLBCLs) with inferior outcomes after standard chemoimmunotherapy.
|
31527075 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our analysis provided a novel look on the transition range between FL and DLBCL, on DLBCL with poor prognosis showing expression patterns resembling that of Burkitt's lymphoma and particularly on 'double-hit' MYC and BCL2 transformed lymphomas.
|
31039827 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tools targeting the BH4 domain of Bcl-2 reverse Bcl-2's inhibitory action on IP3Rs and trigger pro-apoptotic Ca(2+) signaling in cancer B-cells, including chronic lymphocytic leukemia (CLL) cells and diffuse large B-cell lymphoma (DLBCL) cells.
|
24768714 |
2014 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For these reasons, we evaluated single-agent activity of venetoclax in the DLBCLs and identified a subset with limited sensitivity to BCL-2 blockade despite having genetic bases of BCL-2 dysregulation.
|
30322870 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim was to investigate MYC, Bcl-2 and Bcl-6 translocations and copy number changes in adult DLBCLs to evaluate their clinicopathological features and prognostic implications.
|
18752503 |
2008 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Correlation with Bcl-2 immunostaining showed that of seven patients with high-grade cutaneous diffuse large B-cell lymphoma, four were Bcl-2 positive but had no evidence of a t(14;18) translocation.
|
11298531 |
2001 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined 25 cases of colorectal lymphoma with DLBCL-like morphology and classified them into germinal center B-cell like (GCB)/non-GCB subgroups by immunohistochemistry (IHC) for CD10, bcl-6 and MUM1, or into double-expressor (DE)/non-DE subgroups by IHC for bcl-2 and c-myc.
|
31734190 |
2020 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The bcl-2 gene rearrangement is quite frequent in follicular lymphoma, followed by diffuse large B-cell lymphoma.
|
19537891 |
2009 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Unlike systemic diffuse large B-cell lymphoma, del(6)(q22) is common and IGH translocations are infrequent and usually involve BCL6 rather than BCL2, suggesting a distinct pathogenesis.
|
18645192 |
2008 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
On the basis of immunohistochemical MYC and BCL2 expression, a double-hit score (DHS) was assigned to all patients with DLBCL.
|
22665537 |
2012 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vivo repression of MYC and BCL2 in combination with cyclophosphamide also significantly slowed tumor growth in DLBCL xenograft mice.
|
28605593 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified ID3 mutations in lymphomas with chromosomal aberrations at cMYC and either BCL2 or BCL6 at a frequency intermediate between that of DLBCL and Burkitt lymphoma, hinting at a common pathway in lymphomagenesis for a subset of patients with DHL.
|
24222112 |
2013 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Translocations involving IGH were detected in 36 (32%) of 111 cases; their partner genes included BCL6 (n = 10), c-MYC (n = 5), and FOXP1 (n = 3) but remained unknown in the remaining 18 cases. t(14;18)/IGH-BCL2, t(14;18)/IGH-MALT1, and t(1;14)/BCL10-IGH were not detected in any case. t(11;18)/API2-MALT1 was detected in none of the cases, except for one case of DLBCL with MALT lymphoma, which showed positive signals only in MALT lymphoma cells.
|
18445693 |
2008 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.
|
16670080 |
2006 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Many of the cases in this DLBCL/BL category contain a translocation of MYC as well as BCL2, so-called "double-hit lymphomas" which have a very aggressive clinical behavior.
|
22035756 |
2011 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The rearrangements of C-MYC, BCL2 and/or BCL6 which are common in diffuse large B-cell lymphoma (DLBCL) are typically absent in PLMBCL.
|
31728727 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We initially designed 4-grade BCL2 scoring criteria, from 0 to 3+, and found that ∼40% of DLBCL showed strong BCL2 expression (score 3+).
|
28522442 |
2017 |